Ovascience (OVAS) Shares are Down -14.76%

Ovascience (OVAS) has risen sharply, recording gains of 13.29% in the past 4 weeks. However, the stock has corrected -14.76% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 13.9% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

The stock has recorded a 20-day Moving Average of 1.87% and the 50-Day Moving Average is 12.01%.The 200 Day SMA reached 1.42%

Ovascience

Ovascience (NASDAQ:OVAS): The stock opened in the green at $7.26 on Friday, but the bulls found it difficult to push the prices higher. The stock reached a high of $7.3 and a low of $6.96 for the day. The stock did not find buyers even at the lows and closed at $7.16 recording a loss of -0.97%. 651,911 shares exchanged hands during the trading day. The stock had closed at $7.16 in the previous days trading.

Ovascience (OVAS) : The most positive equity analysts on Ovascience (OVAS) expects the shares to touch $15, whereas, the least positive believes that the stock will trade at $8 in the short term. The company is covered by 3 Wall Street Brokerage Firms. The average price target for shares are $10.33 with an expected fluctuation of $4.04 from the mean.

OvaScience, Inc. is a global fertility company. The Company is focused on the discovery, development and commercialization of new fertility treatments based on egg precursor or EggPC cells, which are immature egg cells found in the protective outer layer of a womans own ovaries. With the Companys AUGMENT treatment, energy-producing mitochondria from a patients own EggPC cells are added to the patients mature eggs during the In vitro fertilization (IVF) process to supplement the existing mitochondria. Its OvaPrime treatment is designed to replenish a womans egg reserve by transferring a patients EggPC cells from the protective ovarian lining back into the patients own ovaries where they may mature into fertilizable eggs during the IVF process. The OvaTure treatment seeks to mature a womans own EggPC cells into eggs outside her body. The OvaXon is a joint venture with Intrexon Corporation to create new applications to prevent inherited diseases for human and animal health.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.